There will be no buyout at $12.Ganetespib's pipeline is huge and the BOD knows it.
On 6/24,the price broke hard through the BB's which is a positive despite the fact that it reversed from $4.54 to $4.20.
My trend lines still point to mid $20's....$30 plus or more,possibly before this year is over.
Keep in mind,SNTA has to announce FDA approval for only one Ganetespib application.
The rest will follow.
As to whether the shorts are still running the show or will get burned has yet to be seen